TICKERNOMICS Sign up
Last Update: 2024-03-28 02:10:31
Axsome Therapeutics Inc. ( AXSM ) https://www.axsome.com
76.72USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
AXSM
24.73%
SPY
32.74%
AXSM
29.51%
SPY
92.93%
AXSM
439.14%
SPY
224.41%
AXSM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3632.80
3424.67
0.59
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-17.52
16.26
19.02
-5.49
0.00
-18.07
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-107.49
88.70
-73.77
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.7531
-73.13
-72.62
1.47
Other Earnings and Cash Flow Stats:
Axsome Therapeutics Inc. ( AXSM ) Net Income TTM ($MM) is -187.41
Axsome Therapeutics Inc. ( AXSM ) Operating Income TTM ($MM) is -166.83
Axsome Therapeutics Inc. ( AXSM ) Owners' Earnings Annual ($MM) is 0.00
Axsome Therapeutics Inc. ( AXSM ) Current Price to Owners' Earnings ratio is 0.00
Axsome Therapeutics Inc. ( AXSM ) EBITDA TTM ($MM) is -159.69
Axsome Therapeutics Inc. ( AXSM ) EBITDA Margin is -73.77%
Capital Allocation:
Axsome Therapeutics Inc. ( AXSM ) has paid 0.00 dividends per share and bought back -6.695422 million shares in the past 12 months
Axsome Therapeutics Inc. ( AXSM ) has increased its debt by 82.961766 million USD in the last 12 months
Capital Structure:
Axsome Therapeutics Inc. ( AXSM ) Interest-bearing Debt ($MM) as of last quarter is 178
Axsome Therapeutics Inc. ( AXSM ) Annual Working Capital Investments ($MM) are -7
Axsome Therapeutics Inc. ( AXSM ) Book Value ($MM) as of last quarter is 190
Axsome Therapeutics Inc. ( AXSM ) Debt/Capital as of last quarter is 93%
Other Balance Sheet Stats:
Axsome Therapeutics Inc. ( AXSM ) has 386 million in cash on hand as of last quarter
Axsome Therapeutics Inc. ( AXSM ) has 138 million of liabilities due within 12 months, and long term debt 178 as of last quarter
Axsome Therapeutics Inc. ( AXSM ) has 47 common shares outstanding as of last quarter
Axsome Therapeutics Inc. ( AXSM ) has 0 million USD of preferred stock value
Academic Scores:
Axsome Therapeutics Inc. ( AXSM ) Altman Z-Score is 3.58 as of last quarter
Axsome Therapeutics Inc. ( AXSM ) Piotroski Score is 0.00 as of last quarter
Corporate Governance:
Axsome Therapeutics Inc. ( AXSM ) largest shareholder is owning shares at 0.00 ($MM) value
JEFFS ROGER(an insider) Sold 2347 shares of Axsome Therapeutics Inc. ( AXSM ) for the amount of $168062.10 on 2024-03-15
17.14% of Axsome Therapeutics Inc. ( AXSM ) is held by insiders, and 70.65% is held by institutions
Axsome Therapeutics Inc. ( AXSM ) went public on 2015-11-19
Other Axsome Therapeutics Inc. ( AXSM ) financial metrics:
FCF:-139.83
Unlevered Free Cash Flow:-123.93
EPS:-5.25
Operating Margin:-107.49
Gross Profit Margin:88.70
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-130.28
Beta:1.47
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Axsome Therapeutics Inc. ( AXSM ) :
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.